Luscetta, student nurse
Real Victoza® patient
Starting A1C: 9.8%
Help patients initiate Victoza® by setting expectations.
Use the titration system to manage nausea from the start
Individual results may vary.
While some patients experience nausea with Victoza®, for most it lessens over time1
A 26-week, open-label, active-comparator, parallel-group, multicenter study to compare the safety and efficacy of Victoza® with exenatide in patients not adequately controlled on metformin or sulfonylurea or both. Patients with type 2 diabetes (N=464) were stratified by previous oral antidiabetic therapy and randomized to receive once-daily Victoza® 1.8 mg (n=233) or exenatide 10 µg BID (n=231) in combination with metformin and/or sulfonylurea. The primary outcome was change in A1C.1
In the pool of 5 placebo-controlled clinical trials, withdrawals due to gastrointestinal adverse reactions occurred in 4.3% of Victoza®-treated patients and 0.5% of placebo-treated patients. Withdrawal due to gastrointestinal adverse events mainly occurred during the first 2 to 3 months of the trials.
Reference: 1. Buse JB, Rosenstock J, Sesti G, et al; for the LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.